Exact Expects FDA Approval For Cologuard Plus In Second Half Of 2024, Featuring 30% Lower False-Positive Rate Compared To Original Cologuard, Improving Cancer Sensitivity And Specificity
Portfolio Pulse from Benzinga Newsdesk
Exact Sciences anticipates FDA approval for Cologuard Plus in the second half of 2024. The new test offers a 30% lower false-positive rate and improved cancer sensitivity and specificity compared to the original Cologuard.

September 11, 2024 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences is expecting FDA approval for its new Cologuard Plus test in the second half of 2024. The test features a 30% reduction in false-positive rates and improved cancer detection capabilities, which could enhance its market position.
The anticipated FDA approval of Cologuard Plus, with its improved accuracy, is likely to positively impact Exact Sciences' market position and stock price. The enhancements in false-positive rates and cancer detection make it a more attractive option for healthcare providers and patients, potentially increasing sales and revenue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100